Breaking News

The firm has reached a deal with certain investors for the purchase of units comprising OncoCyte common shares and warrants to purchase shares.

Namocell has partnered with the two firms to distribute its cell dispensing tool in South Korea, the Netherlands, Belgium, and Luxembourg.

A PCR-based analysis of nearly 700 cases picked up human papillomavirus or human polyomaviruses DNA in a fraction of urothelial bladder carcinoma tumors.

While the '3G' study did not establish clinical utility, the researchers said it shows genomic profiling to guide gastric cancer treatment is feasible.

Using genotype and phenotype data from the UK Biobank project, a Stanford investigator uncovered variants linked to low bone mineral density.

The ACE ImmunoID test uses exome and transcriptome sequencing to identify neoantigens for the development of personalized cancer vaccines.

Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.

Revenues for Roche Diagnostics totaled CHF 6.26 billion for H1, driven primarily by demand for immunodiagnostic solutions.

The team will use a S$1.5 million grant to develop a database of mutations that cause hereditary breast and gynecological cancers in Asian women.

The test, which uses automated reverse-transcription real-time PCR, expands the firm's menu of CLIA-waived tests for use in near-patient and point-of-care settings.

The WGS workflow for diagnosing pediatric genetic diseases uses off-the-shelf products and fits into standard diagnostic laboratory procedures.

A 19-miRNA panel showed high sensitivity and specificity for differentiating benign and malignant thyroid nodules.

Cigna began covering the company's ThyGeNext next-generation sequencing-based test for thyroid cancer risk assessment in 2017.

The China-based company said that it now has 11 products that have been CE marked, and has applied for additional CE certification for other tests.

Researchers used brain expression data from mice with well-documented sleep traits to identify gene networks that overlap with those in human depression.

The company's revenues totaled $6.08 billion, up from $4.99 billion during Q2 of 2017.

Public sector programs in some low- and middle-income countries will obtain access to Hologic's Panther system through a single, all-inclusive pricing structure.

The company said it plans to use the financing to increase adoption of its MammaPrint BluePrint next-generation sequencing-based test kit for breast cancer.

The firm will manufacture its Logix Smart mycobacteria tuberculosis assay at its ISO-certified facility in Utah but will not seek FDA approval at this time, it said.

The firm will use the proceeds for working capital, but said it may also acquire or invest in complementary technologies or businesses.

The companies will initially contribute equally to funding the collaboration and will share in future proceeds from drugs developed within the partnership.

The STRIDES program aims to establish industry partnerships to provide NIH researchers access to cost-effective computational infrastructure, tools, and services.

The funding from the Mark Foundation for Cancer Research will support an initiative to investigate cancer genomics in ethnically diverse populations.

The agency is seeking one or two sequencing centers for the Gabriella Miller Kids First Research Program.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.